Literature DB >> 3901726

Hemodynamic principles in the control of coronary blood flow.

S E Epstein, R O Cannon, T L Talbot.   

Abstract

The effects of atherosclerotic epicardial stenoses on coronary vascular resistance can be understood in terms of basic principles of fluid mechanics. Resistance is directly related to the pressure drop across the stenosis and inversely related to flow. Even with a fixed anatomic stenosis, however, resistance is not fixed; it increases as flow across the stenosis increases. This exacerbates the pressure drop across the stenosis that develops as a result of flow; at high flows, large pressure drops can occur. This characteristic of flow through stenotic lesions can contribute to a "steal" phenomenon between either epicardial or intramural coronary arteries. Studies have also shown the clinical importance and influence of dynamic alterations in coronary resistance, occurring either at the large or small vessel level. In addition, compressive forces exerted by the myocardium or by elevated intraventricular pressures can increase coronary vascular resistance, and thus interfere with myocardial perfusion. All of these factors must be considered in order to obtain a comprehensive understanding of the mechanisms leading to myocardial ischemia and, therefore, to the clinical syndrome of angina pectoris.

Entities:  

Mesh:

Year:  1985        PMID: 3901726     DOI: 10.1016/0002-9149(85)91169-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

Review 1.  Advancements in pharmacotherapy for angina.

Authors:  Ankur Jain; Islam Y Elgendy; Mohammad Al-Ani; Nayan Agarwal; Carl J Pepine
Journal:  Expert Opin Pharmacother       Date:  2017-03-15       Impact factor: 3.889

2.  Pharmacology of the coronary circulation.

Authors:  J C Sill
Journal:  Can J Anaesth       Date:  1987-05       Impact factor: 5.063

Review 3.  Congenital anomalies of the coronary arteries.

Authors:  Michael Hauser
Journal:  Heart       Date:  2005-09       Impact factor: 5.994

4.  Impaired coronary blood flow may be related to elevated homocysteine levels in patients with metabolic syndrome.

Authors:  Yusuf I Alihanoglu; Bekir S Yildiz; Emin E Özcan; Ismail D Kilic; Deniz S Kuru; Ozgur Taskoylu; Halil Tanriverdi; Havane A Kaftan; Harun Evrengul
Journal:  Wien Klin Wochenschr       Date:  2015-09-16       Impact factor: 1.704

5.  Acute phase proteins activation in subjects with coronary atherosclerosis and micro-vessel coronary circulation impairment.

Authors:  Natale Daniele Brunetti; Roberto Padalino; Luisa De Gennaro; Andrea Cuculo; Luigi Ziccardi; Pier Luigi Pellegrino; Matteo Di Biase
Journal:  J Thromb Thrombolysis       Date:  2008-08-09       Impact factor: 2.300

6.  Coronary blood flow is slower in prediabetic and diabetic patients with normal coronary arteries compared with nondiabetic patients.

Authors:  Uğur Arslan; Mustafa Mücahit Balcı; Ibrahim Kocaoğlu
Journal:  Exp Clin Cardiol       Date:  2012

7.  Coronary vasomotor and clinical effects of nifedipine in effort, mixed and Prinzmental angina.

Authors:  A Polese; N De Cesare; A Bartorelli; F Fabbiocchi; A Loaldi; P Montorsi; M D Guazzi
Journal:  Int J Card Imaging       Date:  1988

8.  Enzymatic activation of endothelial protease-activated receptors is dependent on artery diameter in human and porcine isolated coronary arteries.

Authors:  Justin R Hamilton; James D Moffatt; James Tatoulis; Thomas M Cocks
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

9.  Coronary pressure and flow relationships in humans: phasic analysis of normal and pathological vessels and the implications for stenosis assessment: a report from the Iberian-Dutch-English (IDEAL) collaborators.

Authors:  Sukhjinder S Nijjer; Guus A de Waard; Sayan Sen; Tim P van de Hoef; Ricardo Petraco; Mauro Echavarría-Pinto; Martijn A van Lavieren; Martijn Meuwissen; Ibrahim Danad; Paul Knaapen; Javier Escaned; Jan J Piek; Justin E Davies; Niels van Royen
Journal:  Eur Heart J       Date:  2015-11-26       Impact factor: 29.983

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.